# c-TRAK-TN (NCT03145961)

> A Trial Using ctDNA Blood Tests to Detect Cancer Cells After Standard Treatment to Trigger Additional Treatment in Early Stage Triple Negative Breast Cancer Patients

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03145961
- Phase: PHASE2
- Status: UNKNOWN
- Sponsor: Institute of Cancer Research, United Kingdom
- Conditions: Triple Negative Breast Cancer
- Interventions: Pembrolizumab
- Enrollment: 208
- Primary outcome: Positive ctDNA detection by 12 months
- Primary outcome: Positive ctDNA detection by 24 months
- Primary outcome: Absence of detectable ctDNA or disease recurrence 6 months (24 weeks) after commencing pembrolizumab

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- YouTube: 6
- X threads: 5
- Bluesky threads: 1

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=c-trak-tn-nct03145961

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03145961", "email": "<work email>"}; the inbox owner confirms by the emailed link.